Yungan Tao

机构：Université Paris-Saclay, Institut Gustave Roussy · ORCID：0000-0002-6916-5263

发表论文 176 篇 · 总被引 5761 次 · h-index 40

代表论文

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial (2024 · The Lancet Oncology · 被引 244)
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial (2022 · Annals of Oncology · 被引 192)
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis (2021 · The Lancet Oncology · 被引 112)
International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma (2021 · International Journal of Radiation Oncology*Biology*Physics · 被引 110)
LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) (2022 · Annals of Oncology · 被引 95)
LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial (2021 · Annals of Oncology · 被引 89)